John Higgins, Ligand Pharmaceuticals CEO, joins ‘Power Lunch’ to discuss how the company’s drug discovery technology is helping with the race to find a cure for the coronavirus.
CNBC recently interviewed John Higgins, CEO of Ligand, and asked about the company’s connection to Remdesivir, which is being used in the country’s first clinical trials for an experimental treatment for COFID-19.
Ligand provides Captisol, a component of Remdesivir that makes it soluble and capable of being absorbed by the human body. Captisol was co-invented by BTBC Board member Val Stella and was the initial product of KU spinout company Cydex. Ligand acquired Cydex and transformed Captisol into an internal drug compound with endless applications. Watch the interview to learn more about its application in a potential vaccine for coronavirus.
Find the original article here